New data from the PROCLIPI study has shown a meaningful overall survival benefit for patients with advanced cutaneous T-cell lymphoma (CTCL) treated with POTELIGEO (mogamulizumab).
The findings were presented at the European Organisation for Research and Treatment of Cancer – Cutaneous Lymphoma Tumour Group Annual Meeting in Athens.
The PROCLIPI study is one of the largest international registries in CTCL, spanning 19 countries and including over 2,000 patients. It aims to develop prognostic indices for CTCL subtypes, including mycosis fungoides (MF) and Sézary syndrome (SS).
Among 371 patients with advanced MF and SS, those treated with mogamulizumab (n=72) had a median overall survival of 64 months, compared to 54 months for those not receiving the therapy (n=175). For a subset of SS patients (n=96), median survival was around 6.5 years for those treated with mogamulizumab, versus around 3 years for those receiving systemic treatment without it.
Professor Julia Scarisbrick, Chief Investigator of the PROCLIPI Study, said: “The PROCLIPI Study demonstrates the power of global collaboration in rare diseases. By bringing together data from across the world, we can generate insights that simply wouldn’t be possible in isolation.”
Susan Thornton, CEO of the Cutaneous Lymphoma Foundation, explained: “For those of us in the CTCL community, survival isn’t just about numbers on a chart – it’s about being able to spend more time with our families, plan for the future, and live life with dignity.”
Dr Nick Kronfeld, Head of Medical Affairs at Kyowa Kirin International, said: “These insights into improved overall survival for patients living with CTCL mark an important step forward, providing a stronger clinical evidence base and reinforcing the value of international networks in rare disease research.”
